Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

1.

Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas.

Bur H, Haapasaari KM, Turpeenniemi-Hujanen T, Kuittinen O, Auvinen P, Marin K, Koivunen P, Sormunen R, Soini Y, Karihtala P.

Histopathology. 2014 Sep;65(3):319-27. doi: 10.1111/his.12389. Epub 2014 Apr 3.

PMID:
24698430
[PubMed - in process]
2.

Combination of strong MMP-2 and weak TIMP-2 immunostainings is a significant prognostic factor in endometrial carcinoma.

Honkavuori-Toivola M, Santala M, Soini Y, Turpeenniemi-Hujanen T, Talvensaari-Mattila A.

Dis Markers. 2013;35(4):261-6.

PMID:
24344400
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

[Chemotherapy in conjunction with blood brain barrier disruption in the treatment of primary central nervous system lymphoma].

Kuittinen O, Siniluoto T, Isokangas M, Turpeenniemi-Hujanen T, Peltonen J, Alahuhta S, Sonkajärvi E.

Duodecim. 2013;129(15):1563-70. Review. Finnish.

PMID:
24163974
[PubMed - indexed for MEDLINE]
4.

Increased expression of CIP2A in aggressive subtypes of B-cell lymphoma.

Lilja L, Haapasaari KM, Bloigu R, Salonen T, Ristimäki A, Turpeenniemi-Hujanen T, Kuittinen O.

Histopathology. 2013 Sep;63(3):438-9. doi: 10.1111/his.12162. Epub 2013 Jun 26. No abstract available.

PMID:
23802697
[PubMed - indexed for MEDLINE]
5.

Cell cycle regulation score predicts relapse-free survival in non-germinal centre diffuse large B-cell lymphoma patients treated by means of immunochemotherapy.

Pasanen AK, Haapasaari KM, Peltonen J, Soini Y, Jantunen E, Bloigu R, Turpeenniemi-Hujanen T, Kuittinen O.

Eur J Haematol. 2013 Jul;91(1):29-36. doi: 10.1111/ejh.12117. Epub 2013 May 3.

PMID:
23560495
[PubMed - indexed for MEDLINE]
6.

Circulating matrix metalloproteinase MMP-9 and MMP-2/TIMP-2 complex are associated with spontaneous early pregnancy failure.

Nissi R, Talvensaari-Mattila A, Kotila V, Niinimäki M, Järvelä I, Turpeenniemi-Hujanen T.

Reprod Biol Endocrinol. 2013 Jan 15;11:2. doi: 10.1186/1477-7827-11-2.

PMID:
23320481
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.

Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, Luukkaa M, Nyandoto P, Hemminki A, Nilsson S, McCaffrey J, Asola R, Turpeenniemi-Hujanen T, Laestadius F, Tasmuth T, Sandberg K, Keane M, Lehtinen I, Luukkaala T, Joensuu H; PROSTY study group.

Lancet Oncol. 2013 Feb;14(2):117-24. doi: 10.1016/S1470-2045(12)70537-5. Epub 2013 Jan 4.

PMID:
23294853
[PubMed - indexed for MEDLINE]
8.

Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma.

Peroja P, Pasanen AK, Haapasaari KM, Jantunen E, Soini Y, Turpeenniemi-Hujanen T, Bloigu R, Lilja L, Kuittinen O, Karihtala P.

Exp Hematol Oncol. 2012 Mar 26;1(1):2. doi: 10.1186/2162-3619-1-2.

PMID:
23210982
[PubMed]
Free PMC Article
9.

Biological roles and prognostic values of the epithelial-mesenchymal transition-mediating transcription factors Twist, ZEB1 and Slug in diffuse large B-cell lymphoma.

Lemma S, Karihtala P, Haapasaari KM, Jantunen E, Soini Y, Bloigu R, Pasanen AK, Turpeenniemi-Hujanen T, Kuittinen O.

Histopathology. 2013 Jan;62(2):326-33. doi: 10.1111/his.12000. Epub 2012 Nov 27.

PMID:
23190132
[PubMed - indexed for MEDLINE]
10.

Snail promotes an invasive phenotype in lung carcinoma.

Merikallio H, Turpeenniemi-Hujanen T, Pääkkö P, Mäkitaro R, Riitta K, Salo S, Salo T, Harju T, Soini Y.

Respir Res. 2012 Nov 17;13:104. doi: 10.1186/1465-9921-13-104.

PMID:
23157169
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Tumor tissue inhibitor of metalloproteinases-1 (TIMP-1) in hormone-independent breast cancer might originate in stromal cells, and improves stratification of prognosis together with nodal status.

Kuvaja P, Hulkkonen S, Pasanen I, Soini Y, Lehtonen S, Talvensaari-Mattila A, Pääkkö P, Kaakinen M, Autio-Harmainen H, Hurskainen T, Lehenkari P, Turpeenniemi-Hujanen T.

Exp Cell Res. 2012 Jun 10;318(10):1094-103. doi: 10.1016/j.yexcr.2012.03.009. Epub 2012 Mar 23.

PMID:
22465225
[PubMed - indexed for MEDLINE]
12.

Immunoreactivity for TIMP-2 is associated with a favorable prognosis in endometrial carcinoma.

Honkavuori-Toivola M, Talvensaari-Mattila A, Soini Y, Turpeenniemi-Hujanen T, Santala M.

Tumour Biol. 2012 Aug;33(4):935-41. doi: 10.1007/s13277-012-0321-7. Epub 2012 Jan 21.

PMID:
22270451
[PubMed - indexed for MEDLINE]
13.

Long-term prognosis of breast cancer detected by mammography screening or other methods.

Lehtimäki T, Lundin M, Linder N, Sihto H, Holli K, Turpeenniemi-Hujanen T, Kataja V, Isola J, Joensuu H, Lundin J.

Breast Cancer Res. 2011;13(6):R134. doi: 10.1186/bcr3080. Epub 2011 Dec 28.

PMID:
22204661
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Expression and prognostic evaluation of oxidative stress markers in an immunohistochemical study of B-cell derived lymphomas.

Pasanen AK, Kuitunen H, Haapasaari KM, Karihtala P, Kyllönen H, Soini Y, Turpeenniemi-Hujanen T, Kuittinen O.

Leuk Lymphoma. 2012 Apr;53(4):624-31. doi: 10.3109/10428194.2011.624226. Epub 2011 Dec 13.

PMID:
21929285
[PubMed - indexed for MEDLINE]
15.

Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.

Sihto H, Lundin J, Lundin M, Lehtimäki T, Ristimäki A, Holli K, Sailas L, Kataja V, Turpeenniemi-Hujanen T, Isola J, Heikkilä P, Joensuu H.

Breast Cancer Res. 2011 Sep 13;13(5):R87. doi: 10.1186/bcr2944.

PMID:
21914172
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study.

Peltonen JK, Vähäkangas KH, Helppi HM, Bloigu R, Pääkkö P, Turpeenniemi-Hujanen T.

Head Neck Oncol. 2011 Apr 22;3:20. doi: 10.1186/1758-3284-3-20.

PMID:
21513535
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

8-hydroxydeguanosine and nitrotyrosine are prognostic factors in urinary bladder carcinoma.

Soini Y, Haapasaari KM, Vaarala MH, Turpeenniemi-Hujanen T, Kärjä V, Karihtala P.

Int J Clin Exp Pathol. 2011 Mar;4(3):267-75. Epub 2011 Mar 2.

PMID:
21487522
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53.

Väisänen A, Kuvaja P, Kallioinen M, Turpeenniemi-Hujanen T.

Hum Pathol. 2011 Aug;42(8):1103-11. doi: 10.1016/j.humpath.2010.11.013. Epub 2011 Feb 21.

PMID:
21334717
[PubMed - indexed for MEDLINE]
19.

Very high quantitative tumor HER2 content and outcome in early breast cancer.

Joensuu H, Sperinde J, Leinonen M, Huang W, Weidler J, Bono P, Kataja V, Kokko R, Turpeenniemi-Hujanen T, Jyrkkiö S, Isola J, Kellokumpu-Lehtinen PL, Paquet A, Lie Y, Bates M.

Ann Oncol. 2011 Sep;22(9):2007-13. doi: 10.1093/annonc/mdq710. Epub 2011 Feb 1.

PMID:
21285132
[PubMed - indexed for MEDLINE]
Free Article
20.

Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer.

Konsti J, Lundin M, Joensuu H, Lehtimäki T, Sihto H, Holli K, Turpeenniemi-Hujanen T, Kataja V, Sailas L, Isola J, Lundin J.

BMC Clin Pathol. 2011 Jan 25;11:3. doi: 10.1186/1472-6890-11-3.

PMID:
21262004
[PubMed]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk